Health insurers recruiting former pharma reps to cut costs

June 19, 2017

(HealthDay)—Health insurers are recruiting former pharmaceutical company representatives to educate doctors and help save money on prescription medications, according to a report published June 8 in Kaiser Health News.

Noting that costs for have been rising faster than those for any other health segment, and others paying those costs are trying to address the increases.

Capital District Physicians' Health Plan (CDPHP), an Albany, N.Y., insurer, is hiring former pharma representatives and staffing a sales force to develop cost-effective medicine. They have been able to address rising costs of , such as Glumetza (metformin hydrochloride), manufactured by Valeant Pharmaceuticals, which reached a price of $81,270 per year. When CDPHP doctors were informed of the price, most of the 60 plan members who were taking Glumetza were switched to the generic alternative, saving $5 million in one year.

"Insurers are taking matters into their own hands," said Lea Prevel Katsanis, a marketing professor at Concordia University in Montreal, according to the article. "They're saying, 'We can't really rely on drug companies to talk to doctors about what's cost-efficient.'"

Explore further: Leading U.S. doctors' group takes aim at rising drug prices

More information: More Information

Related Stories

Leading U.S. doctors' group takes aim at rising drug prices

June 15, 2017
(HealthDay)—The American Medical Association is calling for more transparency in drug pricing amid skyrocketing costs that are putting some lifesaving medications out of reach for patients and communities.

Rising costs and potential savings for generic, topical steroids

April 29, 2017
Although topical steroids are among the most commonly prescribed medications by dermatologists, there are limited data on spending and use for this class of drugs. In a new study led by investigators at Brigham and Women's ...

Examining the rising costs of prescription drugs in the US, and possible alternatives

April 4, 2017
Prescription drugs are already unaffordable for many: The price tag last year in the United States was $425 billion, one out of every 10 health care dollars spent, and rising.

US health care spending up five percent in 2015

November 22, 2016
(HealthDay)—Privately insured Americans spent nearly 5 percent more on health care last year than in 2014, largely because of escalating prices, new research shows.

AMA urges doctors to talk about safe opioid storage, disposal

April 29, 2017
(HealthDay)—Physicians should take three essential steps to reduce the amount of unwanted, unused, and expired medications in an effort to avoid non-medical uses of the drugs, according to a new recommendation from the ...

Prices skyrocket on drugs widely used by seniors: report

December 14, 2016
(HealthDay)—The prices of brand-name drugs used by many older Americans rose nearly 130 times faster than inflation last year, a new study reports.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.